CytomX Therapeutics reports a Schedule 13G showing Point72-affiliated holders beneficially own 10,864,581 shares of Common Stock, representing 5.0% of the class as of the close of business on April 15, 2026. The filing states the 216,177,309 shares outstanding figure is the sum of 45,990,567 shares issued in a March 18, 2026 offering and 170,186,742 shares outstanding as of February 28, 2026.
The statement is filed jointly by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen under a Joint Filing Agreement and cites shared voting and dispositive power over the reported shares.
Positive
None.
Negative
None.
Insights
Point72 holds a disclosed 5.0% stake (10,864,581 shares) in CytomX as of April 15, 2026.
The filing shows shared voting and dispositive power reported by Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen under a Joint Filing Agreement pursuant to Rule 13d-1(k). The ownership percentage is calculated on 216,177,309 shares outstanding, combining a March 18, 2026 offering and a February 28, 2026 outstanding count.
Watch future filings for any Schedule 13D amendments or changes in shared/sole power; subsequent filings would clarify whether activity is passive or active.
Key Figures
Shares beneficially owned:10,864,581 sharesPercent of class:5.0%Shares outstanding (basis):216,177,309 shares
3 metrics
Shares beneficially owned10,864,581 sharesReported by Point72 affiliates as of April 15, 2026
Percent of class5.0%Calculated on 216,177,309 shares outstanding
Shares outstanding (basis)216,177,309 sharesSum of 45,990,567 shares from March 18, 2026 offering and 170,186,742 as of February 28, 2026
"Amount beneficially owned: The information required by Item 4(a) is set forth"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shared Dispositive Powerregulatory
"Shared Dispositive Power 10,864,581.00"
Joint Filing Agreementlegal
"have entered into a Joint Filing Agreement, a copy of which is filed"
Rule 13d-1(k)regulatory
"file this jointly in accordance with the provisions of Rule 13d-1(k)"
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
CytomX Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.00001 per share
(Title of Class of Securities)
23284F105
(CUSIP Number)
04/15/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
23284F105
1
Names of Reporting Persons
Point72 Asset Management, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
10,864,581.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
10,864,581.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
10,864,581.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
23284F105
1
Names of Reporting Persons
Point72 Capital Advisors, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
10,864,581.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
10,864,581.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
10,864,581.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
23284F105
1
Names of Reporting Persons
Steven A. Cohen
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
10,864,581.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
10,864,581.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
10,864,581.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
CytomX Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
151 Oyster Point Blvd, Suite 400, South San Francisco, California 94080
Item 2.
(a)
Name of person filing:
This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.00001 per share ("Common Stock"), of CytomX Therapeutics, Inc. (the "Issuer") held by Point72 Associates, LLC, an investment fund it manages ("Point72 Associates"); (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to the shares of Common Stock held by Point72 Associates; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to the shares of Common Stock beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.
Each of Cubist Systematic Strategies, LLC, Point72 (DIFC) Limited and Point72 Europe (London) LLP are relying advisers on the Form ADV of Point72 Asset Management and each acts as a sub-advisor with respect to a portion of the Common Stock reported herein.
Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934 (the "Act").
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
(c)
Citizenship:
Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
(d)
Title of class of securities:
Common Stock, par value $0.00001 per share
(e)
CUSIP Number(s):
23284F105
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on April 15, 2026.
Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no shares of Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.
The aggregate percentage of shares of Common Stock reported to be beneficially owned by each Reporting Person is based on 216,177,309 shares of Common Stock outstanding, which is the sum of (i) 45,990,567 shares of Common Stock issued in the offering described in the Issuer's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission (the "SEC") on March 18, 2026, and (ii) 170,186,742 shares of Common Stock outstanding as of February 28, 2026, as reported in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 16, 2026.
(b)
Percent of class:
5.0%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on April 15, 2026.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on April 15, 2026.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on April 15, 2026.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on April 15, 2026.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a). Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Common Stock.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Point72-affiliated filers report beneficial ownership of 10,864,581 shares, representing 5.0% of CytomX Common Stock as of April 15, 2026. The holdings are reported jointly by Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen under a Joint Filing Agreement.
How was the 5.0% ownership percentage calculated for CTMX?
The percentage is based on 216,177,309 shares outstanding, which the filing states is the sum of 45,990,567 shares issued in a March 18, 2026 offering and 170,186,742 shares outstanding as of February 28, 2026, per the filing's disclosed sources.
Who among Point72 reports voting and dispositive power for the CTMX shares?
The filing attributes shared voting and shared dispositive power over the reported 10,864,581 shares to Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen; each reporting person states they own no shares directly and report shared power.
Does this Schedule 13G indicate active control or trading intent by Point72?
The Schedule 13G filing reports passive beneficial ownership under Rule 13d-1(k) and a Joint Filing Agreement; it does not itself state intentions to trade or exert active control. Any change to active intent would typically require a Schedule 13D amendment.
